PACB
Pacific Biosciences Of California, Inc. Health Care Laboratory Analytical Instruments Russell 3000
$2.61Close
$788.1MMarket cap
$1.14 – $2.9052-week range
Nov 4, 2026Next report · after the close
Highlights
Strengths
- Accumulation up-day volume 2.0× down-day volume over 50 sessions
Cautions
- Extended 4.0 ATR above its 50-day average
- Results soon Nov 4, 2026, in 3 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
10%
1wk
up 23.7%
price change
1mo
up 10.1%
price change
12-month return
up 127%
total, dividends included
F-score
4 / 9
Weak
Altman Z
-5.87
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
147.3×
price / book
Earnings yield
down 76.5%
EBIT / enterprise value
Cheaper than
2%
of the market · expensive
Revenue growth
up 4%
year on year
EPS growth
—
latest quarter
Sales growth
down 2%
latest quarter · -2 pts
ROE
down 213%
return on equity
Free cash margin
down 71%
-$113.9M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Piotroski tests
- not yet profitable on its assets
- operating cash flow is negative
- profitability slipped from last year
- short-term liquidity weakened
- issued more shares
- profits backed by cash
- reduced long-term debt
- gross margin widened
- assets working harder
Repair signals
- Gross margin 24.2% → 28.6%
- Revenue reaccelerating (-23% then +4%)
Trade setup
ATR%
10.5%
$0.27 a day · 2×ATR $2.06
RS
—
vs the universe
Trend
—
trend template
Relative volume
1.1×
vs 50-day average
Up/down volume
1.98
50 sessions
Implied move
—
no option chain · report Nov 4, 2026
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Shareholders diluted The share count rose 2.6% over the year, from 294m to 302m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 5, 2026
Last shock
Oct 8, 2026-15% in one session1.9× volumeno filing matched+13% since
Financials
- Gross 29%
- Net -341%
- Free cash -71%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $78.9M | $130.5M | $128.3M | $200.5M | $154.0M | $160.0M |
| Gross margin | 41% | 45% | 38% | 26% | 24% | 29% |
| Operating income | -$104.4M | -$210.4M | -$307.2M | -$334.5M | -$474.3M | -$553.9M |
| Net income | $29.4M | -$181.2M | -$314.2M | -$306.7M | -$309.9M | -$546.4M |
| Net margin | 37% | -139% | -245% | -153% | -201% | -341% |
| Earnings per share | $0.17 | -$0.89 | -$1.40 | -$1.21 | -$1.07 | -$1.82 |
| Free cash flow | $18.5M | -$117.1M | -$280.0M | -$268.0M | -$212.2M | -$113.9M |
| Free cash margin | 23% | -90% | -218% | -134% | -138% | -71% |
| Cash | $81.6M | $460.7M | $325.1M | $179.9M | $55.4M | $63.7M |
| Long-term debt | — | $896.1M | $896.7M | $500,000 | — | — |
| Shareholders' equity | $335.5M | $791.0M | $562.9M | $701.3M | $506.6M | $5.3M |
| Shares outstanding | 192.29m | 220.98m | 226.50m | 267.74m | 294.42m | 301.96m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 6, 2026 | Quarterly ↗ | Jun 30, 2026 | 37d |
| May 8, 2026 | Quarterly ↗ | Mar 31, 2026 | 38d |
| Feb 25, 2026 | Annual ↗ | Dec 31, 2025 | 56d |
| Nov 6, 2025 | Quarterly ↗ | Sep 30, 2025 | 37d |
| Aug 7, 2025 | Quarterly ↗ | Jun 30, 2025 | 38d |
| May 12, 2025 | Quarterly ↗ | Mar 31, 2025 | 42d |
| Mar 17, 2025 | Annual ↗ | Dec 31, 2024 | 76d |
| Nov 12, 2024 | Quarterly ↗ | Sep 30, 2024 | 43d |
| Aug 9, 2024 | Quarterly ↗ | Jun 30, 2024 | 40d |
| May 9, 2024 | Quarterly ↗ | Mar 31, 2024 | 39d |
| Feb 28, 2024 | Annual ↗ | Dec 31, 2023 | 59d |
| Nov 3, 2023 | Quarterly ↗ | Sep 30, 2023 | 34d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 5, 2026 | Results · Restructuring · Director or officer change · Regulation FD ↗ |
| Jul 9, 2026 | Director or officer change ↗ |
| Jun 4, 2026 | Director or officer change · Shareholder vote ↗ |
| May 7, 2026 | Results ↗ |
| Mar 6, 2026 | Director or officer change · Regulation FD ↗ |
| Mar 5, 2026 | Director or officer change · Regulation FD ↗ |
| Feb 12, 2026 | Results ↗ |
| Feb 3, 2026 | Director or officer change ↗ |
| Feb 2, 2026 | Material agreement · Acquisition or disposal · Regulation FD ↗ |
| Jan 12, 2026 | Results · Other events ↗ |
| Nov 5, 2025 | Results ↗ |
| Aug 7, 2025 | Results ↗ |